Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 12, 2007
JNCI Journal of the National Cancer Institute 2007 99(12):973-974; doi:10.1093/jnci/djm003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/12/973-a    most recent
djm003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tam-McDevitt, J.
Right arrow Articles by Lichtman, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tam-McDevitt, J.
Right arrow Articles by Lichtman, S.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Response: Re: Has Demand for Clinical Trial Participants Outpaced Supply?

Jennifer Tam-McDevitt, Lodovico Balducci, Robert Hauser, Stuart Lichtman

Affiliations of authors: Geriatric Oncology Consortium, Baltimore, MD (JTM, RH); Senior Adult Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL (LB); Department of Medicine, Memorial Sloan-Kettering Cancer Center, Commack, NY (SL)

Correspondence to: Jennifer Tam-McDevitt, PharmD, PhD, Geriatric Oncology Consortium, 3600 Clipper Mill Rd, Ste 110, Baltimore, MD 21211 (e-mail: jtam@thegoc.org).

The first 10% of the full text of this article appears below.

We thank Go et al. for their comments about our study, which has generated active discussions with various organizations since its presentation at the 2006 American Society for Clinical Oncology meeting.

Our finding that the demand for trial participants may be outpacing the supply was based on current estimates that only 5%–10% of all . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Has Demand for Clinical Trial Participants Outpaced Supply?
Ronald S. Go, Lori A. Meyer, and Kathleen A. Frisby
J Natl Cancer Inst 2007 99: 973. [Extract] [Full Text] [PDF]